Alpha Crest Capital Management LLC Intellia Therapeutics, Inc. Transaction History

Alpha Crest Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$58.27 - $118.99 $109,372 - $223,344	-1,877 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$100.76 - $138.36 $189,126 - $259,701	1,877 New	1,877 $222,000
Q1 2021 May 13, 2021	SELL	$46.59 - $83.68 $428,628 - $769,856	-9,200 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$18.83 - $63.53 $679,762 - $2.29 Million	-36,100 Reduced 79.69%	9,200 $500,000
Q3 2020 Nov 12, 2020	BUY	$17.47 - $24.93 $791,391 - $1.13 Million	45,300 New	45,300 $901,000
Q3 2019 Nov 12, 2019	SELL	$13.07 - $18.51 $202,585 - $286,905	-15,500 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$13.88 - $18.41 $74,952 - $99,414	5,400 Added 53.47%	15,500 $254,000
Q1 2019 May 10, 2019	BUY	$12.79 - $17.62 $129,178 - $177,962	10,100 New	10,100 $173,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $921M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.